Thalys(SH:603716) Sou Hu Cai Jing·2025-06-28 18:00Core Viewpoint - The company, Sely Medical, has experienced a significant increase in stock price and has made announcements regarding the use of idle funds and credit rating adjustments [1][2][3]. Group 1: Stock Performance - As of June 27, 2025, Sely Medical's stock closed at 13.91 yuan, up 14.49% from the previous week [1]. - The stock reached a peak price of 14.2 yuan and a low of 11.65 yuan during the week [1]. - The company's current total market capitalization is 2.657 billion yuan, ranking 30th in the pharmaceutical commercial sector and 4521st in the A-share market [1]. Group 2: Company Announcements - Sely Medical plans to use up to 32.5 million yuan of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months [2]. - As of May 31, 2025, the company had utilized 201.8791 million yuan of the 2020 convertible bond funds, achieving an overall investment progress of 37.90% [2]. - The board and supervisory committee approved the use of idle funds, stating it would enhance fund efficiency and lower financial costs without affecting the normal use of raised funds [2]. Group 3: Credit Rating Adjustment - The credit rating for Sely Medical's convertible bonds has been adjusted from "BBB-" to "BB+" with a stable outlook [3]. - The previous rating was established on February 18, 2025, and the new rating was issued following a tracking analysis by Zhongceng Pengyuan Credit Rating Co., Ltd. [3]. - The adjusted rating means that the "Sely Convertible Bonds" can no longer be used as collateral for repurchase transactions [3].